



(51) International Patent Classification:

C07D 401/14 (2006.01) **C07D 413/04** (2006.01)
C07D 213/81 (2006.01) **C07D 417/04** (2006.01)
C07D 401/04 (2006.01) **C07D 417/12** (2006.01)
C07D 401/12 (2006.01) **A61K 31/4427** (2006.01)
C07D 405/04 (2006.01) **A61K 31/4436** (2006.01)
C07D 409/04 (2006.01) **A61P 25/28** (2006.01)

(21) International Application Number:

PCT/US2014/063666

(22) International Filing Date:

3 November 2014 (03.11.2014)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

61/900,547 6 November 2013 (06.11.2013) US

(71) Applicant: **BRISTOL-MYERS SQUIBB COMPANY**
[US/US]; Route 206 and Province Line Road, Princeton,
New Jersey 08543 (US).(72) Inventors: **LUO, Guanglin**; c/o Bristol-Myers Squibb
Company, 5 Research Parkway, Wallingford, Connecticut
06492 (US). **CHEN, Ling**; c/o Bristol-Myers Squibb Com-
pany, 5 Research Parkway, Wallingford, Connecticut


06492 (US). **DUBOWCHIK, Gene M.**; c/o Bristol-Myers
Squibb Company, 5 Research Parkway, Wallingford, Con-
necticut 06492 (US). **JACUTIN-PORTE, Swanee E.**; c/o
Bristol-Myers Squibb Company, 5 Research Parkway,
Wallingford, Connecticut 06492 (US).
SIVAPRAKASAM, Prasanna; c/o Bristol-Myers Squibb
Company, 5 Research Parkway, Wallingford, Connecticut
06492 (US). **MACOR, John E.**; c/o Bristol-Myers Squibb
Company, Route 206 and Province Line Road, Princeton,
New Jersey 08543 (US).

(74) Agents: **EPPERSON, James** et al.; Bristol-Myers Squibb
Company, Route 206 and Province Line Road, Princeton,
New Jersey 08543 (US).(81) Designated States (*unless otherwise indicated, for every
kind of national protection available*): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY,
BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR,
KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG,
MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM,
PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC,
SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

[Continued on next page]

(54) Title: SUBSTITUTED PYRIDINE DERIVATIVES USEFUL AS GSK-3 INHIBITORS

(57) Abstract: The disclosure generally relates to compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds are ligands, antagonists of the NR2B receptor and may be useful for the treatment of various disorders of the central nervous system.





(84) **Designated States** (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*
- *of inventorship (Rule 4.17(iv))*

Published:

- *with international search report (Art. 21(3))*